A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
Items 301–400 of 1,000
Early lymphoid lesions: conceptual, diagnostic and clinical challenges
Ganapathi, K. A., Pittaluga, S., Odejide, O. O., Freedman, A. S., & Jaffe, E. S. (2014) · Haematologica · doi:10.3324/haematol.2014.107938 · Cited by 56
“The incidence of MGUS increases with age and has a small but definitive risk of progression to myeloma at an annual rate of 1%.(9) Multiple factors affect the progression of MGUS to myeloma.”
BackgroundRajkumar, S. V., Merlini, G., & Miguel, J. F. S. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.128 · Cited by 63
Self-citationMonoclonal gammopathies of undetermined significance
Kyle, R. A., & Rajkumar, S. V. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.025 · Cited by 56
Self-citationKyle, R. A., Benson, J. T., Larson, D. R., Therneau, T. M., Dispenzieri, A. A., Melton, L. J., & Rajkumar, S. V. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.002 · Cited by 56
Self-citationLaboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities
Murray, D. L., Seningen, J. L., Dispenzieri, A., Snyder, M. R., Kyle, R. A., Rajkumar, S. V., & Katzmann, J. A. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpt6owwmhita1y · Cited by 55
Self-citationCan we change the disease biology of multiple myeloma?
Borrello, I. (2012) · Leukemia Research · doi:10.1016/s0145-2126(12)70003-6 · Cited by 61
“The reasons why MGUS progresses to MM in only a small proportion of patients are unclear, and both genetic and environmental factors have been implicated [2].”
BackgroundInfluentialPlasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms
Coker, W. J., Jeter, A., Schade, H. H., & Kang, Y. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-8 · Cited by 59
Cancer-Immune Equilibrium: Questions Unanswered
Bhatia, A., & Kumar, Y. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0065-8 · Cited by 55
“The adaptive T cells are the key players in the maintenance of this dormant status [6].”
BackgroundResultSchmid, J. P., Junge, S., Hossle, J. P., Schneider, E. M., Roosnek, E. E., Seger, R. A., & Güngör, T. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2062 · Cited by 64
Asymptomatic Waldenstrom's macroglobulinemia
Alexanian, R., Weber, D., Delasalle, K. B., Cabanillas, F., & Dimopoulos, M. A. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50051 · Cited by 55
Sigurbergsdóttir, A. Ý., Rögnvaldsson, S., Þorsteinsdóttir, S., Sverrisdottir, I. S., Sigurðardóttir, G. Á., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., Sigurðardóttir, M. S., Þorsteinsdóttir, I., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283191 · Cited by 59
“Since, by definition, those with clinical MGUS had had MGUS for a longer time, and because Mprotein generally increases over time, these results were expected.(24) Both groups had a relatively low mean M-protein concentration (0.”
Drake, M. T. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2387 · Cited by 56
“Because MGUS produces no overt symptoms and is frequently identified during the course of routine medical care or during evaluation of an unrelated disorder,((17)) >50% patients have had MGUS for >10 years and 30% for >20 years before clinical recognition.”
BackgroundMicroRNA: Important Player in the Pathobiology of Multiple Myeloma
Bi, C., & Chng, W. J. (2014) · BioMed Research International · doi:10.1155/2014/521586 · Cited by 59
“MM is always preceded by an asymptomatic premalignant stage called monoclonal gammopathy of undetermined significance (MGUS), which progresses to myeloma or related malignancies at a rate of 1% per year [4, 5].”
BackgroundAbramson, H. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155192 · Cited by 57
Royer, R. H., Koshiol, J. E., Giambarresi, T. R., Vasquez, L. G., Pfeiffer, R. M., & McMaster, M. L. (2010) · Blood · doi:10.1182/blood-2009-10-247973 · Cited by 54
Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma
Bi, C., Chung, T., Huang, G., Zhou, J., Yan, J., Ahmann, G. J., Fonseca, R., & Chng, W. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4769 · Cited by 58
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A. A., Melton, L. J., Benson, J. T., Kumar, S. K., & Rajkumar, S. V. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)70001-8 · Cited by 53
Self-citationPremalignant Lesions as Targets for Cancer Vaccines
Finn, O. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031787 · Cited by 53
“(5) focus on patients with preneoplastic gammopathy (MGUS), a clonal expansion of transformed plasma cells that is a direct precursor of multiple myelomas (17).”
BackgroundVanValkenburg, M. E., Pruitt, G. I., Brill, I. K., Costa, L., Ehtsham, M., Justement, I. T., Innis-Shelton, R. D., Salzman, D., Reddy, E. S. P., Godby, K. N., et al. (2016) · Cancer Causes & Control · doi:10.1007/s10552-015-0685-2 · Cited by 51
“Although the etiology of MM is unclear, it is preceded by an asymptomatic plasma cell dyscrasia known as Monoclonal Gammopathy of Undetermined Significance (MGUS) [3, 4] that carries a risk of progression to frank MM of 1 % per year [5].”
BackgroundShaughnessy, J. D., & Barlogie, B. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00054.x · Cited by 56
“Approximately 1% of all MGUS cases will convert to overt MM per year (3), but it is virtually impossible to predict which of these cases will convert.”
BackgroundInfluentialOsteoblastogenesis and tumor growth in myeloma
Yaccoby, S. (2010) · Leukemia & Lymphoma · doi:10.3109/10428190903503438 · Cited by 52
“Patients with monoclonal gammopathy of undetermined significance (MGUS), a benign disease with an annual conversion rate of 1% to overt myeloma, do not have typical osteolytic lesions seen in patients with active MM [5].”
Monoclonal Gammopathy of Undetermined Significance
Gonsalves, W. I., & Rajkumar, S. V. (2022) · Annals of Internal Medicine · doi:10.7326/aitc202212200 · Cited by 53
Self-citationOkasaki, M., Kubota, K., Minamimoto, R., Miyata, Y., Morooka, M., Ito, K., Ishiwata, K., Toyohara, J., Inoue, T., Hirai, R., et al. (2014) · Annals of Nuclear Medicine · doi:10.1007/s12149-014-0931-9 · Cited by 51
“In MGUS, the overall risk of progression is about 1 % per year [28], and the median duration of MGUS and SMM before a diagnosis of myeloma is 81 and 23 months, respectively [29].”
Backgroundda Silva, S. P., Resnick, E. S., Lucas, M., Lortan, J. E., Patel, S. Y., Cunningham‐Rundles, C., Gatter, K. C., Liu, Q., Jaffe, E. S., & Chapel, H. M. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9565-z · Cited by 51
“less than 50% develop overt life-threatening malignancy over 30+ years [34].”
BackgroundCastillo, J. J. (2016) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2016.07.002 · Cited by 53
“AL amyloidosis, light chain deposition disease, and other lymphoproliferative disorders.(11) Patients with IgMMGUS can progress intoWM, and rarely, into AL amyloidosis or IgM MM.”
BackgroundBergstrom, D. J., Kotb, R. R., Louzada, M., Sutherland, H. J., Tavoularis, S., Venner, C. P., Côté, J. A., LeBlanc, R., Reiman, T., Sébag, M., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.017 · Cited by 60
“MGUS is a condition with low risk of conversion to overtly symptomatic disease requiring therapy (w1% per year).(9,10) The risk of evolution to symptomatic disease rises with increasing clonal PC burden and is defined as smoldering MM (SMM), an intermediate stage associated with a higher risk of progression to overt M…”
BackgroundMorra, E., Cesana, C., Klersy, C., Barbarano, L., Varettoni, M., Cavanna, L., Canesi, B., Tresoldi, E., Miqueleiz, S., Bernuzzi, P., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403442 · Cited by 50
SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma
Noll, J. E., Hewett, D. R., Williams, S. A., Vandyke, K., Kok, C. H., To, L. B., & Zannettino, A. C. W. (2014) · Neoplasia · doi:10.1016/j.neo.2014.07.002 · Cited by 55
“at a rate of 1% per year; however, the time to progression varies greatly between patients [5].”
BackgroundGame of Bones: How Myeloma Manipulates Its Microenvironment
Moser-Katz, T., Joseph, N. S., Dhodapkar, M. V., Lee, K. P., & Boise, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.625199 · Cited by 53
“Patients diagnosed with MGUS have a 1% risk per year of progressing to symptomatic myeloma, and therefore the standard of care is surveillance without intervention (23).”
BackgroundMR Imaging Evaluation of the Bone Marrow and Marrow Infiltrative Disorders of the Lumbar Spine
Alyas, F., Saifuddin, A., & Connell, D. (2007) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2007.03.002 · Cited by 50
Fracture risk in patients with monoclonal gammopathy of undetermined significance
Gregersen, H., Jensen, P., Gislum, M., Jørgensen, B., Sørensen, H. T., & Nørgaard, M. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06269.x · Cited by 50
“MGUS confers an increased risk of malignant transformation to symptomatic malignant monoclonal gammopathy, most often to multiple myeloma (MM) and less frequently other malignant lymphoproliferative disorders (Kyle et al, 2002).”
BackgroundLight chain amyloidosis 2012: a new era
Gatt, M. E., & Palladini, G. O. (2013) · British Journal of Haematology · doi:10.1111/bjh.12191 · Cited by 51
“For instance, it is known that evolution to AL amyloidosis accounts for 10% of all progressions in patients with a monoclonal gammopathy of undetermined significance (Kyle et al, 2002, 2004), and the risk is particularly high in subjects with an altered FLC j/k ratio.”
BackgroundKourelis, T., Kumar, S. K., Go, R. S., Kapoor, P., Kyle, R. A., Buadi, F. K., Gertz, M. A., Lacy, M. Q., Hayman, S. R., Leung, N., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23827 · Cited by 49
“Discussion In this study, we demonstrate that a small minority of patients diagnosed with AL amyloidosis, have a previously identified “asymptomatic” PCD—most commonly MGUS, followed by SMM and SWM.”
BackgroundInfluentialSelf-citationThe role of the bone marrow microenvironment in multiple myeloma.
Raeve, H. R. D., & Vanderkerken, K. (2005) · PubMed · doi:10.14670/hh-20.1227 · Cited by 54
“During long-term follow-up 25 % of patients with MGUS will develop MM or IgM expressing lymphoma, primary amyloidosis, macroglobulinaemie, chronic lymphocytic leukaemia or plasmocytoma, at a rate of 1% per year (Kyle et al., 2002).”
BackgroundLymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment
von Beck, K., von Beck, T. A., Ferrell, P. B., Bick, A. G., & Kishtagari, A. (2023) · Blood Cancer Journal · doi:10.1038/s41408-022-00773-8 · Cited by 54
Raheja, D., Specht, C., & Simmons, Z. (2014) · Muscle & Nerve · doi:10.1002/mus.24471 · Cited by 49
“5, respectively), with a cumulative risk of transformation to a malignant disorder of 12% at 10 years, 25% at 20 years, and 30% at 25 years.(24) This has led experts to recommend lifelong monitoring of serum immunoglobulin levels on a yearly basis; any significant increase should lead to an evaluation by a hematologis…”
BackgroundMultiple myeloma – current issues and controversies
Kumar, S. K. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70006-2 · Cited by 54
Castillo, J. J., Callander, N. S., Baljević, M., Sborov, D. W., & Kumar, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26155 · Cited by 47
Iwanaga, M., Tagawa, M., Tsukasaki, K., Matsuo, T., Yokota, K., Miyazaki, Y., Fukushima, T., Hata, T., Imaizumi, Y., Imanishi, D., et al. (2008) · Blood · doi:10.1182/blood-2008-05-159665 · Cited by 56
“Not determined 21 (2) 1 (1) Serum M-protein level, no.”
Disorders of Peripheral Nerves
Harati, Y., & Bosch, E. P. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7506-7525-3.50118-7 · Cited by 49
Fan, S., Price, T. T., Huang, W., Plue, M., Warren, J. L., Sundaramoorthy, P., Paul, B. A., Feinberg, D. M., MacIver, N. J., Chao, N. J. A., et al. (2020) · Advanced Science · doi:10.1002/advs.201900860 · Cited by 51
Hutchison, C. A., Burmeister, A., Harding, S. J., Basnayake, K., Church, H., Jesky, M., White, K. M., Green, C. E., Stringer, S. J., Bassett, P., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.028 · Cited by 48
Chim, C. S., Liang, R. H. S., Leung, M.-H., & Kwong, Y. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.036715 · Cited by 50
“Multiple myeloma develops in about one quarter of MGUS patients after a median of 10 years.”
BackgroundThe skinny on obesity and plasma cell myeloma: a review of the literature
Carson, K. R., Bates, M. L., & Tomasson, M. H. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.71 · Cited by 48
Weiss, B. M., Minter, A., Abadie, J., Howard, R., Ascencao, J., Schechter, G. P., Kuehl, M., & Landgren, O. (2011) · American Journal of Hematology · doi:10.1002/ajh.22025 · Cited by 48
“The identification of high-risk features for transformation from MGUS to MM has been derived from predominantly white populations, raising the question whether these biomarkers are applicable to other populations [5,15,16].”
BackgroundKristinsson, S. Y., Minter, A. R., Korde, N., Tan, E., & Landgren, O. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.44 · Cited by 49
One‐step targeted maximum likelihood estimation for time‐to‐event outcomes
Cai, W., & van der Laan, M. J. (2019) · Biometrics · doi:10.1111/biom.13172 · Cited by 66
“…of color refers to that version gammopathy study, an observational survival analysis dataset that first established the predictive relationship between the initial concentration of serum monoclonal protein and the progression to multiple myeloma or another plasma-cell cancer (Kyle et al., 2002).”
BackgroundUrbán, V. S., Ceglédi, A., & Mikala, G. (2022) · GeroScience · doi:10.1007/s11357-022-00698-x · Cited by 45
“MGUS progresses to multiple myeloma or related malignancies at a steady rate of 1% per year [13], meaning that MGUS diagnosis may precede the development of MM by more than 10 years [14].”
BackgroundPlasma Cell Neoplasms in US Solid Organ Transplant Recipients
Engels, E. A., Clarke, C. A., Pfeiffer, R. M., Lynch, C. F., Weisenburger, D. D., Gibson, T. M., Landgren, O., & Morton, L. M. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12234 · Cited by 46
“monoclonal gammopathy of undetermined significance [MGUS]) indicates the presence of an abnormal clone of plasma cells and is associated with the subsequent development of multiple myeloma (31).”
BackgroundMolecular pathogenesis of Waldenstrom's macroglobulinemia
Braggio, E., Philipsborn, C., Novak, A. J., Hodge, L. S., Ansell, S. M., & Fonseca, R. (2012) · Haematologica · doi:10.3324/haematol.2012.068478 · Cited by 49
“Patients with monoclonal gammopathy of undetermined significance (MGUS) are at increased risk for progression to WM.(20) In a population-based study of 1,384 individuals with MGUS, researchers showed an increased risk factor of 46 for developing WM.”
BackgroundMouse models of multiple myeloma: technologic platforms and perspectives
Rossi, M., Botta, C., Arbitrio, M., Grembiale, R. D., Tagliaferri, P., & Tassone, P. (2018) · Oncotarget · doi:10.18632/oncotarget.24614 · Cited by 46
Medical management update: Multiple myeloma
Stoopler, E. T., Vogl, D. T., & Stadtmauer, E. A. (2007) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2006.10.026 · Cited by 50
Inherited genetic susceptibility to monoclonal gammopathy of unknown significance
Weinhold, N., Johnson, D. C., Rawstron, A. C., Försti, A., Doughty, C., Vijayakrishnan, J., Broderick, P., Dahir, N. B., Begum, D. B., Hosking, F. J., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532283 · Cited by 43
“MGUS is relatively common and is detectable in the plasma of;2% of individuals older than age 50 years, and with each advancing year, the risk of MGUS progressing to MM is ;1%.(2) No lifestyle or environmental exposure factors have been identified that are consistently linked to either an increased risk of MMorMGUSor…”
BackgroundAdvances in the Treatment of Paraproteinemic Neuropathy
Nobile‐Orazio, E., Bianco, M., & Nozza, A. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0479-9 · Cited by 43
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 48
“It is not surprising that MM genomes also possess mutations in the genes encoding chromatin remodelers and their interacting partners, including CHD2, CHD4, ARID1A, ARID2, ATRX, and ZFHX4 [9,82,86,415].”
BackgroundFarr, J. N., Zhang, W. Y., Kumar, S. K., Jacques, R., Ng, A. C., McCready, L. K., Rajkumar, S. V., & Drake, M. T. (2013) · Blood · doi:10.1182/blood-2013-05-505776 · Cited by 43
Self-citationMultiple myeloma: New staging systems for diagnosis, prognosis and response evaluation
Rajkumar, S. V., & Buadi, F. K. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.10.002 · Cited by 47
Self-citationPrognostic features of multiple myeloma
Miguel, J. F. S., & García‐Sánz, R. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.012 · Cited by 43
Feng, Y., Yang, S., Zhang, B., & Wei, B. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s102733 · Cited by 42
Targeting signalling pathways for the treatment of multiple myeloma
Podar, K., Hideshima, T., Chauhan, D., & Anderson, K. C. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.2.359 · Cited by 43
“In primary plasma cell leukaemia (PCL), CD70-triggered activation of CD27 mediates modest antiapoptotic effects involving ERK1/2 MAPK [138].”
BackgroundBlotta, S., Tassone, P., PRABHALA, R. H., Tagliaferri, P., Cervi, D. N., Amin, S. B., Jakubíková, J., Tai, Y., Podar, K., Mitsiades, C. S., et al. (2009) · Blood · doi:10.1182/blood-2009-04-219436 · Cited by 44
Clinical characteristics and outcomes in biclonal gammopathies
Mullikin, T. C., Rajkumar, S. V., Dispenzieri, A. A., Buadi, F. K., Lacy, M. Q., Lin, Y., Dingli, D., Go, R. S., Hayman, S. R., Zeldenrust, S. R., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24319 · Cited by 42
“Currently, the progression of monoclonal disease is well established in that MGUS progresses to MM at 1% per year, whereas SMM is more aggressive, progressing to MM at an approximate rate of 10% per year during the initial 5 years [10,11].”
BackgroundSelf-citationManagement of paraproteinaemia
Cook, L. B. M., & Macdonald, D. H. C. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.054627 · Cited by 52
van Dussen, L., Biegstraaten, M., Dijkgraaf, M. G. W., & Hollak, C. E. M. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0112-x · Cited by 41
“MGUS in itself is not a malignancy, but in the general population the yearly risk of transition from an MGUS to a multiple myeloma or other lymphatic malignancy is 1% [57].”
BackgroundEndothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall
Tenreiro, M. M. B., Correia, M. L., & Brito, M. A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9571-8 · Cited by 43
Neuropathy and monoclonal gammopathy
Nobile‐Orazio, E. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52902-2.00025-4 · Cited by 44
Risk factors for monoclonal gammopathy of undetermined significance: a systematic review
Castañeda‐Avila, M. A., Ulbricht, C. M., & Epstein, M. M. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04400-7 · Cited by 43
Acquired von Willebrand Syndrome Associated With Monoclonal Gammopathy
Voisin, S., Hamidou, M. A., Lefrançois, A., Sigaud, M., Mahé, B., & Trossaërt, M. (2011) · Medicine · doi:10.1097/md.0b013e3182397166 · Cited by 41
Brousseau, M., Leleu, X. P., Gerard, J., Gastinne, T., Godon, A., Geneviève, F., Dib, M., Laï, J., Facon, T. T. F., Zandecki, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0031 · Cited by 41
Diet and risk of multiple myeloma in Connecticut women
Hosgood, H. D., Baris, D., Zahm, S. H., Zheng, T., & Cross, A. J. (2007) · Cancer Causes & Control · doi:10.1007/s10552-007-9047-z · Cited by 41
“Beyond monoclonal gammopathy of undetermined significance (MGUS), a predisposing condition with one percent annual risk of progression to myeloma [7], age, and race, little is known about risk factors for multiple myeloma [6].”
BackgroundAccelerated and Interpretable Oblique Random Survival Forests
Jaeger, B. C., Welden, S., Lenoir, K. M., Speiser, J. L., Segar, M. W., Pandey, A., & Pajewski, N. M. (2023) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.2023.2231048 · Cited by 44
“The “Monoclonal gammopathy” data [Kyle et al., 2002] were obtained from the survival R package [Therneau, 2022a].”
MethodMultiple Myeloma and Exposure to Pesticides: A Canadian Case-Control Study
Pahwa, P., Karunanayake, C. P., Dosman, J. A., Spinelli, J. J., McDuffie, H. H., & McLaughlin, J. R. (2011) · Journal of Agromedicine · doi:10.1080/1059924x.2012.632339 · Cited by 41
“With MGUS being a premalignant disorder that precedes MM, 33 the biological plausibility of a role for pesticides in MM etiology can be assessed in part by examining pesticide–MGUS relationships.”
BackgroundIgD Heavy-Chain Deposition Disease
Royal, V., Quint, P. S., Leblanc, M., LeBlanc, R., Duncanson, G. F., Perrizo, R. L., Fervenza, F. C., Kurtin, P. J., & Sethi, S. M. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014050481 · Cited by 40
Hematological manifestations and complications of Gaucher disease
Linari, S., & Castaman, G. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1112732 · Cited by 40
“The MGUS is considered a pre-malignant condition in MM and a progression is observed in about 1% of patients per year [45] in the general population.”
BackgroundWadhera, R. K., Kyle, R. A., Larson, D. R., Dispenzieri, A. A., Kumar, S. K., Lazarus, H. M., & Rajkumar, S. V. (2011) · Blood · doi:10.1182/blood-2011-04-349175 · Cited by 44
“Months from MM diagnosis till onset of secondary MGUS 12 (1-189)”
BackgroundSelf-citationPrognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
Lakshman, A., Paul, S., Rajkumar, S. V., Ketterling, R. P., Greipp, P. T., Dispenzieri, A. A., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0030-3 · Cited by 41
“The lower prevalence of del(17p) in MGUS may be due to [1] low incidence, since it is a secondary abnormality [2], its presence only in a small percentage of PCs, below the threshold for detection or [3] more rapid progression of patients with del(17p).”
BackgroundSelf-citationPolyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders
Mittermayr, S., Le, G. N., Clarke, C., Millán‐Martín, S., Larkin, A., O’Gorman, P., & Bones, J. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00768 · Cited by 40
Miyano, K., Nonaka, M., Uzu, M., Ohshima, K., & Uezono, Y. (2018) · Frontiers in Nutrition · doi:10.3389/fnut.2018.00093 · Cited by 45
“Multiple myeloma (MM) is an incurable malignancy of plasma cells and includes the involvement of chemokines, cytokines and growth factors secreted from MM (19).”
BackgroundThe diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types
Varga, C., Dorbala, S., Lousada, I., Polydefkis, M. J., Wechalekar, A. D., Maurer, M. S., & Comenzo, R. L. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100720 · Cited by 39
Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal
Ríos, R., Paiva, B., Lahuerta, J. J., Martínez‐López, J., & Duarte, R. F. (2022) · Cancers · doi:10.3390/cancers14215247 · Cited by 42
“Overall, p ople with MGUS have a glob l risk f progression of appr ximat ly 1% per year [9], with IgM and non-IgM different modes of pr gression [10].”
BackgroundCoexistence of Myeloproliferative Neoplasm and Plasma-Cell Dyscrasia
Malhotra, J. D., Kremyanskaya, M., Schorr, E. M., Hoffman, R., & Mascarenhas, J. O. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.09.015 · Cited by 39
Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance
Rajkumar, S. V. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1575 · Cited by 43
“The main clinical significance of MGUS is its lifelong risk of transformation to myeloma or related malignancy, at a fixed but unrelenting rate of 1% per year (3).”
BackgroundSelf-citationRawstron, A. C., Bennett, F. L., & Hillmen, P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06863.x · Cited by 42
“The rate of disease progression and some of the risk factors are known and it is therefore possible to provide patients with clear information (Kyle et al, 2002).”
BackgroundDNA Methylation of Tumor Suppressor Protein-Coding and Non-Coding Genes in Multiple Myeloma
Wong, K. Y., & Chim, C. S. (2015) · Epigenomics · doi:10.2217/epi.15.57 · Cited by 42
Bianchi, G., & Ghobrial, I. M. (2014) · Current Cancer Therapy Reviews · doi:10.2174/157339471002141124121404 · Cited by 41
“It was recently reported that MGUS, a precancerous condition characterized by 1%/year rate of progression to neoplasia, consistently precedes MM [31, 32].”
BackgroundMultiple myeloma and persistence of drug resistance in the age of novel drugs (Review)
KRISHNAN, S. R., JAISWAL, R., BROWN, R. D., LUK, F., & BEBAWY, M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3516 · Cited by 35
Wolkersdörfer, G. W., Haase, M., Morgner, A., Baretton, G. B., & Miehlke, S. (2006) · Helicobacter · doi:10.1111/j.1523-5378.2006.00443.x · Cited by 38
Mutational landscape reflects the biological continuum of plasma cell dyscrasias
Rossi, A., Voigtlaender, M., Janjetovic, S., Thiele, B., Alawi, M., März, M., Brandt, A. P., Hansen, T., Radloff, J., Schön, G., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.19 · Cited by 44
Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders
Zanwar, S., & Rajkumar, S. V. (2025) · Leukemia · doi:10.1038/s41375-025-02654-y · Cited by 44
Self-citationImpact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
Goyal, G., Rajkumar, S. V., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Dispenzieri, A. A., Hwa, Y. L., Fonder, A. L., Hobbs, M., Hayman, S. R., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0419-7 · Cited by 39
Self-citationMultiple myeloma—A painful disease of the bone marrow
Diaz‐delCastillo, M., Chantry, A., Lawson, M. A., & Heegaard, A. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.10.006 · Cited by 41
Myeloma and bone disease: "the dangerous tango".
Epstein, J., & Walker, R. C. (2006) · PubMed · Cited by 38
McMaster, M. L., Kristinsson, S. Y., Turesson, I., Björkholm, M., & Landgren, O. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.003 · Cited by 36
Awada, H., Thapa, B., Awada, H., Dong, J., Gurnari, C., Hari, P., & Dhakal, B. (2021) · Cells · doi:10.3390/cells10081961 · Cited by 35
“MM is a heterogeneous disease characterized by the acquisition of complex genetic changes during disease evolution from the premalignant condition monoclonal gammopathy of undetermined significance (MGUS) [7] and smoldering MM (SMM) [8].”
BackgroundMonoclonal gammopathy of undetermined significance and risk of venous thromboembolism
Gregersen, H., Nørgaard, M., Severinsen, M. T., Engebjerg, M. C., Jensen, P., & Sørensen, H. T. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01539.x · Cited by 36
Babel, N., Schwarzmann, F., Prüß, A., Volk, H., & Reinke, P. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.09.046 · Cited by 36
Malignant transformation in polyneuropathy associated with monoclonal gammopathy
Eurelings, M., Lokhorst, H. M., Kalmijn, S., Wokke, J. H. J., & Notermans, N. C. (2005) · Neurology · doi:10.1212/01.wnl.0000166040.32654.27 · Cited by 36
“Monoclonal protein level, mean (SD), g/L 3 (6) 7 (9)* 3 (5) 10 (9)†”
Chang, H., Yeung, J., Xu, W., Ning, Y., & Patterson, B. J. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06237.x · Cited by 41
“Over time, approximately 25% of MGUS patients develop MM or other B-cell lymphoproliferative disorders (Kyle et al, 2002).”
BackgroundHelicobacter pylori infection and monoclonal gammopathy of undetermined significance
Rajkumar, S. V., Kyle, R. A., Plevak, M. F., Murray, J. A., & Therneau, T. M. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03912.x · Cited by 36
“As only 1% of patients with MGUS develop myeloma each year, we did not look at the incidence of myeloma based on H. pylori rate (Kyle et al, 2002).”
BackgroundSelf-citationBustoros, M., Anand, S., Sklavenitis-Pistofidis, R., Redd, R., Boyle, E. M., Zhitomirsky, B., Dunford, A. J., Tai, Y.-T., Chavda, S. J., Boehner, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30694-w · Cited by 35
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.